by Endocrine Therapy Drugs (ETDs) are used in the treatment of hormone-receptor-positive breast cancer and prostate cancer. Some common include Selective Estrogen Receptor Modulators (SERMs), aromatase inhibitors, and other targeted therapies. These drugs work by blocking the action and production of hormones like estrogen and progesterone that fuel cancer growth.
The Global Endocrine Therapy Drugs Market is estimated to be valued at US$ 35060.96 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.
The market has witnessed steady growth owing to rising prevalence of hormone-dependent cancers and increasing adoption of targeted therapies.
Key Takeaways
Key players operating in the Endocrine Therapy Drugs market are Johnson & Johnson (US), Procter & Gamble (US), Kimberly-Clark (US), Essity Aktiebolag (publ) (Sweden), Kao Corporation (Japan), Daio Paper Corporation (Japan), Unicharm Corporation (Japan), Premier FMCG (South Africa), Ontex (Belgium), Hengan International Group Company Ltd. (China), Drylock Technologies (Belgium), Natracare LLC (US), First Quality Enterprises, Inc. (US), Bingbing Paper Co., Ltd. (China). These players dominate the market with their wide geographical presence and diverse product portfolios.
The Endocrine Therapy Drugs Market Growth incidence of breast and prostate cancers worldwide has augmented the demand for effective treatment options like ETDs. According to the National Cancer Institute, over 2 million new cases of breast cancer were reported in 2020.
Several drug manufacturers are investing in R&D to develop novel hormone therapies and expand their geographical presence, especially in emerging Asian markets. Strategic collaborations between pharmaceutical companies are also on the rise to develop advanced targeted therapies.
Market Key Trends
The increasing use of combination therapies that involve ETDs with immunotherapy drugs is a key trend in the market. For example, pairing an aromatase inhibitor with a PD-L1 inhibitor has shown promising results in hormone receptor-positive metastatic breast cancer treatment. Continuous innovation and development of newer targeted formulations with improved safety profiles are expected to define the future course of the Endocrine Therapy Drugs market.
Porter’s Analysis
Threat of new entrants: Low as ETDs market is capital intensive to enter and requires long term R&D investments. Patents and regulations further restrict new players.
Bargaining power of buyers: Moderate as there are few alternatives to ETD treatment. Buyers can negotiate on price being large health systems and insurers.
Bargaining power of suppliers: Moderate as key active ingredients and intermediates have limited suppliers. Suppliers spend on R&D and compliance.
Threat of new substitutes: Low as alternatives like surgery or radiotherapy have downsides. Biologicals being expensive, demand for generic drugs remains.
Competitive rivalry: High as major players vie for patents, market share and profitability is under pricing pressure. Innovations and branding keep competition intense.
Geographical Regions
North America dominates the ETDs market in terms of value holding over 40% share. This is attributed to high cancer incidence, supportive insurance coverage and presence of major players.
Asia Pacific is the fastest growing region for ETDs market owing to rising healthcare spending, growing middle class and increasing cancer cases driven by lifestyle changes and pollution. China and India will be high potential markets.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile
